Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
- Flow cytometry [1]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-24846 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- APITD1 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 400 µL
- Concentration
- 0.5 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references hsa_circ_0077837 Alleviated the Malignancy of Non-Small Cell Lung Cancer by Regulating the miR-1178-3p/APITD1 Axis.
Xu S, Jiang Y, Duan Y
Journal of oncology 2022;2022:3902832
Journal of oncology 2022;2022:3902832
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis using an APITD1 polyclonal antibody (Product # PA5-24846) in mouse NIH-3T3 cell lysates (35 µg per lane).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis in formalin-fixed, paraffin-embedded brain tissue using an APITD1 polyclonal antibody (Product # PA5-24846), followed by HRP-conjugated secondary antibody and DAB staining.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry analysis of Jurkat cells using an APITD1 polyclonal antibody (Product # PA5-24846) (right) compared to a negative control cell (left) at a dilution of 1:10-50, followed by a FITC-conjugated goat anti-rabbit antibody
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 APITD1 was a downstream molecule of miR-1178-3p. (a) TargetScan predicted the potential binding site between miR-1178-3p and APITD1. (b) Dual-luciferase reporter assays detected the regulation of miR-1178-3p on APITD1, and the data were presented as mean +- SEM, ** P < 0.01, miR-1178-3p mimics group vs. miR-1178-3p NC group. (c) miR-1178-3p expression was upregulated in 110 NSCLC tissues in comparison with 110 adjacent tissues, and U6 acted as a control, *** P < 0.001, tumor group vs. adjacent group. (d) APITD1 level affected by miR-1178-3p was detected by western blot, and the data were presented as mean +- SEM, *** P < 0.001, miR-1178-3p mimics group vs. NC group; ### P < 0.001, miR-1178-3p inhibitor group vs. NC group.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Hsa_circ_0077837 overexpression inhibited tumor growth in vivo. (a) Relative hsa_circ_0077837 level was detected by qRT-PCR, and GAPDH act as a control. (b) The tumor volume and weight were lower in over-hsa_circ_0077837 group while higher in si-hsa_circ_0077837 group. (c) Ki-67 immunohistochemistry detected proliferation in over-hsa_circ_0077837 or si-hsa_circ_0077837 group. (d) qRT-PCR analysis detected miR-1178-3p expression in the over-hsa_circ_0077837 or si-hsa_circ_0077837 group. (e) APITD1 expression was detected by western blot. (f) TUNEL staining of the tumors. The data were presented as mean +- SEM, ** P < 0.01, *** P < 0.001, over-hsa_circ_0077837 group vs. control group; ## P < 0.01, ### P < 0.001, si-hsa_circ_0077837 group vs. control group.